Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized placebo-controlled trial of ursodeoxycholic acid in Parkinson's disease
2018-001887-46Phase 2Unknown
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Start
- Jun 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Parkinson's disease (PD) comparing Ursonorm with Placebo (2 arms). Primary endpoint: Safety and tolerability of ursodeoxycholic acid. Status: unknown.
02
Drugs
ursodeoxycholic acid
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on 2018-001887-46.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001887-46.